Pulse Biosciences (PLSE) Cash from Operations (2015 - 2025)

Pulse Biosciences' Cash from Operations history runs 11 years deep, the most recent figure standing at 14755000.0 for Q4 2025.

• On a quarterly basis, Cash from Operations fell 61.36% year-over-year to 14755000.0 in Q4 2025; TTM through Dec 2025 was 54122000.0, a 48.92% decrease from a year earlier, with the FY2025 full-year figure at 54122000.0, down 48.92% from the prior year.
• Cash from Operations slipped to 14755000.0 in Q4 2025 per PLSE's latest filing, from 13039000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 6570000.0 in Q1 2023 and bottomed at 16366000.0 in Q2 2021.
• The 5-year median for Cash from Operations is 11159500.0 (2021), against an average of 11230800.0.
• Across the five-year window, Cash from Operations plunged 106.15% in 2021 and jumped 57.87% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 12694000.0 in 2021, then jumped by 37.25% to 7965000.0 in 2022, then increased by 14.85% to 6782000.0 in 2023, then tumbled by 34.83% to 9144000.0 in 2024, then plunged by 61.36% to 14755000.0 in 2025.
• Per Business Quant, the three latest PLSE Cash from Operations figures stand at 14755000.0 (Q4 2025), 13039000.0 (Q3 2025), and 12807000.0 (Q2 2025).